Editorial: Oxidative stress and distinct cell death

Yanqing Liu, Quanlu Duan, Liping PengFrontiers in Physiology 2023 · DOI · OpenAlex

Abstract

This editorial synthesizes a collection of five papers published in Frontiers in Physiology that explore the intricate link between oxidative stress (OS) and various forms of programmed cell death (PCD), with a particular focus on the iron-dependent process known as ferroptosis. By bridging basic molecular biology with clinical observations, the collection highlights how targeting these death pathways could lead to new treatments for cancer, pulmonary fibrosis, and rheumatoid arthritis.

Introduction: The Balance of Life and Death

Programmed cell death (PCD) is a fundamental biological process, often described as the body’s mechanism for "taking out the trash." It involves predefined suicide missions for cells that are no longer functional or pose a potential threat to the organism. However, when the regulation of PCD fails, it can lead to a wide spectrum of pathologies, including developmental abnormalities, chronic inflammatory diseases, and malignancy.

A primary driver of this dysregulation is oxidative stress (OS)—an imbalance where reactive oxygen species (ROS) overwhelm the body’s antioxidant defenses. While the causal link between OS and cell death is well-established, the specific molecular "how" and "why" remain areas of intense investigation. This Research Topic was curated to clarify the specific regulatory pathways involved and evaluate the translational potential of cell death mechanisms as therapeutic targets.

Methodological Approaches

The editorial summarizes findings from five peer-reviewed papers, including three comprehensive reviews and two original research articles. The methodologies employed across these studies include:

  • Literature Synthesis: In-depth reviews of ferroptosis mechanisms in the context of fibrosis and arthritis.
  • Mendelian Randomization: A two-step genetic analysis used to establish a causal link between smoking, oxidative stress, and lung cancer.
  • Clinical Research: A study of primary liver cancer patients undergoing hepatectomy to evaluate the protective effects of pharmacological interventions, specifically dexmedetomidine, on liver cell survival.

Key Insights: The Rise of Ferroptosis

The collection shifts focus from traditional apoptosis toward ferroptosis, a relatively recently characterized form of regulated cell death driven by iron-dependent lipid peroxidation.

Ferroptosis as a Disease Commonality

Because ROS is the primary initiator of ferroptosis, this pathway serves as a common denominator in diverse conditions ranging from oncogenesis to neurodegeneration. The research suggests that ferroptosis acts as a "Swiss Army Knife" in disease pathology, offering multiple points for therapeutic intervention.

The Interplay of Death Modes

A crucial insight from the collection is that ROS does not trigger a single, isolated type of death. Instead, it can simultaneously or sequentially induce apoptosis, autophagy, and ferroptosis. Understanding this "interplay" is vital for drug design, ensuring that therapies targeting one pathway do not inadvertently activate another harmful death mode.

Genetic and Pharmacological Markers

  • Genetic Susceptibility: One study identified the GSTM1 gene polymorphism as a significant factor in how smoking-induced oxidative stress leads to lung cancer, providing a potential biomarker for clinical risk assessment.
  • Pharmacological Protection: Clinical data suggests that dexmedetomidine, a common sedative, may offer "off-label" benefits by reducing oxidative stress and protecting liver function during major surgical procedures.

Clinical Results and Therapeutic Potential

The Research Topic highlights several high-impact findings:

  • Pulmonary Fibrosis: Identification of natural compounds that specifically target ferroptosis offers a potential "green" chemistry approach to treating lung scarring.
  • Rheumatoid Arthritis: Linking ferroptosis mechanisms to the fundamental pathology of arthritis suggests that ferroptosis-related drugs could significantly reduce joint inflammation.
  • Liver Protection: Clinical trials demonstrated that dexmedetomidine decreases liver cell apoptosis and reduces peripheral immune cell infiltration in the liver, improving post-operative recovery.
  • Lung Cancer: Mendelian randomization confirmed that oxidative stress is the underlying mechanism linking smoking to programmed cell death in lung tissue.

Limitations and Future Directions

Despite these advancements, significant gaps remain. The exact regulatory pathways that determine which type of cell death occurs under specific levels of oxidative stress are not yet fully understood. Furthermore, moving from laboratory-identified natural compounds to clinical pharmaceuticals for fibrosis or arthritis requires extensive validation.

Future research is expected to focus on "precision cell death"—the ability to selectively trigger ferroptosis in malignant cells while shielding healthy tissues. Additionally, newer forms of cell death, such as oxeiptosis (a non-inflammatory death triggered by oxygen), require deeper exploration to fully map the landscape of oxidative stress-induced cellular fate.

Reference: Editorial: Oxidative stress and distinct cell death. Front. Physiol., 21 September 2023. Sec. Cell Physiology. Volume 14 - 2023. doi: 10.3389/fphys.2023.1292044

Summary updated

Abstract

EDITORIAL article Front. Physiol., 21 September 2023Sec. Cell Physiology Volume 14 - 2023 | https://doi.org/10.3389/fphys.2023.1292044
BibTeX
@inproceedings{liu2023editorial,
  author = {Yanqing Liu and Quanlu Duan and Liping Peng},
  title = {{Editorial: Oxidative stress and distinct cell death}},
  booktitle = {Frontiers in Physiology},
  year = {2023},
  doi = {10.3389/fphys.2023.1292044},
}
Figure